RGLS Disappointed, NOVN Loses Face Over Acne Trial Data, AMGN Abuzz

Amgen Inc.’s (AMGN) ABP 501, a biosimilar candidate to AbbVie’s (ABBV) blockbuster arthritis drug Humira, has been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP.

ABP 501 has been recommended for approval by the CHMP for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis, severe ankylosing spondylitis (AS), severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe chronic plaque psoriasis, moderate-to-severe hidradenitis suppurativa, non-infectious intermediate, posterior and panuveitis, moderate-to-severe Crohn’s disease and moderate-to-severe ulcerative colitis.

The CHMP opinion also recommends approval for the treatment of certain pediatric inflammatory diseases, including moderate-to-severe Crohn’s disease…

Read the full article from usatoday.com…

Back to Top